You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Article info

Article menu
Clinical trials monitor
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Authors

  • Carey K Anders Duke Cancer Institute, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Mark G Woodcock Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Amanda E D Van Swearingen Duke Cancer Institute, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Dominic T Moore Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Maria J Sambade Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Sonia Laurie Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Alexander Robeson Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Oleg Kolupaev Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Luz A Cuaboy Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Amy L Garrett Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Karen McKinnon Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Kristen Cowens Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Dante Bortone Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Benjamin C Calhoun Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Alec D Wilkinson Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Lisa Carey Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Trevor Jolly Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Hyman Muss Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Katherine Reeder-Hayes Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Rebecca Kaltman Department of Hematology and Oncology, George Washington Cancer Center, Washington, District of Columbia, USA PubMed articlesGoogle scholar articles
  • Rachel Jankowitz Division of Hematology/Oncology, University of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Vinay Gudena Division of Hematology/Oncology, Cone Health Cancer Center, Greensboro, North Carolina, USA PubMed articlesGoogle scholar articles
  • Oludamilola Olajide Rex Hematology Oncology Associates, Rex Cancer Care, Raleigh, North Carolina, USA PubMed articlesGoogle scholar articles
  • Charles Perou Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • E Claire Dees Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USALineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Benjamin G Vincent Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Hematology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Jonathan S Serody Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Hematology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jonathan S Serody; jonathan_serody{at}med.unc.edu
View Full Text

Citation

Anders CK, Woodcock MG, Van Swearingen AED, et al
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Journal for ImmunoTherapy of Cancer 2022;10:e003427. doi: 10.1136/jitc-2021-003427

Publication history

  • Accepted November 16, 2021
  • First published February 4, 2022.
Online issue publication 
October 18, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.